Coronary artery disease (CAD) is a leading cause of morbidity and mortality worldwide 1,2 . Although 58 genomic regions have been associated with CAD thus far 3-9 , most of the heritability is unexplained 9 , indicating that additional susceptibility loci await identification. An efficient discovery strategy may be larger-scale evaluation of promising associations suggested by genome-wide association studies (GWAS). Hence, we genotyped 56,309 participants using a targeted gene array derived from earlier GWAS results and performed metaanalysis of results with 194,427 participants previously genotyped, totaling 88,192 CAD cases and 162,544 controls. We identified 25 new SNP-CAD associations (P < 5 × 10 −8 , in fixed-effects meta-analysis) from 15 genomic regions, including SNPs in or near genes involved in cellular adhesion, leukocyte migration and atherosclerosis (PECAM1, rs1867624), coagulation and inflammation (PROCR, rs867186 (p.Ser219Gly)) and vascular smooth muscle cell differentiation (LMOD1, rs2820315). Correlation of these regions with celltype-specific gene expression and plasma protein levels sheds light on potential disease mechanisms.
The CardioMetabochip is a genotyping array that contains 196,725 variants of confirmed or suspected relevance to cardiometabolic traits derived from earlier GWAS 10 . A previous meta-analysis by the CARDIoGRAMplusC4D consortium of 79,138 SNPs common to the CardioMetabochip and GWAS arrays identified 15 new loci associated with CAD 3 . Using the CardioMetabochip, we genotyped 56,309 additional samples of European (EUR; ~52%), South Asian (SAS; ~23%), East Asian (EAS; ~17%) and African-American (AA; ~8%) ancestry ( Supplementary Fig. 1, Supplementary Tables 1-3 and Supplementary Note). The results from our association analyses of these additional samples were subjected to meta-analysis with those reported by CARDIoGRAMplusC4D at 79,070 SNPs in two fixed-effects meta-analyses, one in European participants and a second across all four ancestry groups ( Figs. 1 and 2) . (Overlapping samples were removed before meta-analysis; Online Methods.) A genome-wide significance threshold (P ≤ 5 × 10 −8 in the fixed-effects meta-analysis) was adopted to minimize false positive findings, but there is still a small chance of a false positive result. The European fixed-effects meta-analysis identified 15 SNPs associated with CAD at genome-wide significance (P < 5 × 10 −8 ) from nine distinct genomic regions that are not established CAD-associated loci ( Table 1 , Supplementary Fig. 2 and Supplementary Table 4). Six additional distinct new CAD-associated regions were identified in the all-ancestry fixed-effects meta-analysis (Fig. 2 , Table 1 and Supplementary  Table 4 ). In total, 15 new CAD-associated genomic regions (25 SNPs) were identified ( Supplementary Figs. 3 and 4) . The lead SNPs had at least nominal evidence of association (P < 0.05) in either a fixedeffects meta-analysis of the European studies with de novo genotyping or in a fixed-effects meta-analysis of all the studies with de novo Fifteen new risk loci for coronary artery disease highlight arterial-wall-specific mechanisms 1 1 1 4 VOLUME 49 | NUMBER 7 | JULY 2017 Nature GeNetics l e t t e r s genotyping ( Supplementary Fig. 5 and Supplementary Table 5) . Within the CARDIoGRAMplusC4D results for these SNPs, there was no evidence of heterogeneity of effects (P het ≥ 0.10) and allele frequencies were consistent with our European studies (Supplementary Table 5 ). Tests for enrichment of CAD associations within sets of genes 11 and Ingenuity Pathway Analysis confirmed known CAD pathways (Supplementary Tables 6-8 and Supplementary Note).
To prioritize candidate causal genes at the new loci, we defined regions encompassing the new CAD-associated SNPs on the basis of recombination rates (Supplementary Table 9 ) and cross-referenced them with expression quantitative trait locus (eQTL) databases including GTEx 12 , MuTHER 13 and STARNET 14 (Online Methods). Twelve of the 15 new CAD-associated SNPs were identified as potential eQTLs in at least one tissue (P < 5 × 10 −8 ; Table 2 and Supplementary Table 10) . HaploReg analysis 15 (Online Methods) showed that CAD-associated SNPs were enriched for H3K27ac enhancer marks (P < 5.1 × 10 −4 ) in multiple heart-related tissues (left ventricle, right atrium, aorta) in the European results and in one heart-related tissue (right atrium) and liver in the all-ancestry analyses (Supplementary Table 11 ). We next tested for protein quantitative trait loci (pQTLs) in plasma on the aptamer-based Somalogic platform (Online Methods). Twenty-four proteins from the newly identified CAD regions were assayed and passed quality control. Of our 15 new CAD-associated SNPs, 2 associated with plasma protein abundance in trans: rs867186 (NP_006395.2: p.Ser219Gly), a missense variant in PROCR, was a trans-pQTL for protein C (P = 1 × 10 −10 ) and rs1050362 (NP_054722.2:p.Arg140 =), a synonymous variant in DHX38, was a trans-pQTL for apolipoprotein L1 (P = 5.37 × 10 −29 ; Online Methods), which is suggested to interact with HPR in the DHX38 region (String database).
To further help prioritize candidate genes, we also queried the Mouse Genome Informatics database to discover phenotypes resulting from mutations in the orthologous genes for all genes in our 15 CAD-associated regions ( Table 2) . To understand the pathways by which our new loci might be related to CAD risk, we examined the associations of the 15 new CAD regions with a wide range of risk factors, molecular traits and clinical disorders, using PhenoScanner 16 (which encompasses the NHGRI-EBI GWAS catalog and other genotype-phenotype databases).
Six of our loci have previously been associated with known CAD risk factors, such as major lipids (PCNX3 (ref. 17) , C12orf43-HNF1A, SCARB1, DHX38) (ref. 18) ) and blood pressure (GOSR2 (ref. 19) , PROCR 20 ). The sentinel variants for the CAD and risk factor associations at PCNX3, GOSR2 and PROCR were the same, implicating them in known biological pathways. Two correlated SNPs (r 2 = 0.93, D′ = 1.0 in 1000 Genomes Project European samples) rs11057830 and rs11057841 tag the CAD association in the SCARB1 region ( Table 1 and Supplementary Table 4) , a region reported previously to be associated with HDL (rs838876, β = −0.049, P = 7.33 × 10 −33 ) 18 . A rare nonsynonymous variant, rs74830677 (NP_005496.4: p.Pro376Leu) in SCARB1 was also associated with high levels of HDL cholesterol (HDL-C) 21 . Conditional analyses showed that the CAD association was independent of the common variant HDL association ( Supplementary Fig. 6 and Supplementary Note). We found that the CAD SNPs and the common HDL-C SNP rs838880 overlap enhancers active in primary liver tissue (Supplementary Fig. 7 ). SCARB1 is highly expressed in liver and adrenal gland tissues (GTEx; Supplementary Fig. 7 ) 12 . These findings suggest that the discovered genetic variants most likely have a role in regulation of the liverrestricted expression of SCARB1.
The DHX38 region has previously been associated with increased total and LDL cholesterol (LDL-C) 18 . Both CAD-associated SNPs in DHX38, rs1050362 (NP_054722.2:p.Arg140 =) and rs2072142 (synonymous and intronic, respectively; Table 1 and Supplementary  Table 4 ) are in linkage disequilibrium (LD) but are not strongly correlated with the previously reported cholesterol-increasing SNP, intronic in HPR, rs2000999 (r 2 = 0.41, D′ = 1 in 1000 Genomes Project European samples). Deletions in the HP gene have recently been shown to drive the reported cholesterol association in this region 22 . The CAD-associated SNPs are in strong LD with SNPs that increase haptoglobin levels 23 (rs6499560, P = 2.92 × 10 −13 , r 2 = 0.97), and haptoglobin has been reported to be associated with increased CAD risk 24 . HP encodes an α2 glycoprotein that is synthesized in the liver. It binds free hemoglobin and protects tissues from oxidative damage. Mouse models indicate the role of Hp in the development of atherosclerosis 25 , where the underlying mechanism is disruption of the protective nature of the HP protein against hemoglobin-induced injury of atherosclerotic plaque. While the CAD-associated SNPs are eQTLs (or in LD with eQTLs) for multiple genes in the region (for example, DHODH in aorta artery 12 (rs1050362[A] allele, β = 0.41, P = 1.4 × 10 −9 ), DHX38 in peripheral blood 26 and atherosclerotic aortic root 14 (P < 8 × 10 −26 ; Table 2 and Supplementary Table 10)), the A allele at rs1050362 is also associated with increased expression of HP in heart left ventricle (β = 0.535, P = 8.71 × 10 −10 ) 12 and decreased expression of HP in whole blood (β = −0.27, P = 1.22 × 10 −10 ) 12 . While there could be multiple causal genes in the region, together these findings suggest that HP is a promising candidate gene. Figure 1 Schematic of the study design. The sample size information is provided as number of cases/number of controls. Note that samples with de novo genotyping that were also in the CARDIoGRAMplusC4D study were removed before meta-analysis. *, 1,826 CAD cases and 449 controls from EPIC-CVD with de novo genotyping were also included in CARDIoGRAMplusC4D and were therefore excluded from the larger meta-analysis. The actual number of European individuals contributed to the meta-analysis of our studies with de novo genotyping and the CARDIoGRAMplusC4D was 14,267 CAD cases and 16,167 controls. †, 3,704 CAD cases and 3,433 controls from PROMIS with de novo genotyping were also included in CARDIoGRAMplusC4D and were therefore excluded from the larger meta-analysis. The actual number of South Asian samples contributed to the meta-analysis of our studies with de novo genotyping and the CARDIoGRAMplusC4D was 3,950 CAD cases and 3,581 controls. CAD, coronary artery disease; EUR, European ancestry; EAS, East Asian ancestry; SAS, South Asian ancestry; AA, African-American ancestry.
l e t t e r s PROCR encodes the endothelial protein C receptor (EPCR). We found that the G allele at rs867186 (which encodes the glycine residue at p.Ser219Gly) in PROCR confers protection from CAD (odds ratio (OR) = 0.93, 95% confidence interval (CI) = 0.91-0.96; Table 1 and Supplementary Fig. 8 ). The same variant is also associated with increased circulating levels of soluble EPCR (which does not enhance protein C activation) 27 , increased levels of protein C 28 , increased factor VII levels 29 and increased risk of venous thrombosis 27 . Consistent with these associations, the variant has also been demonstrated to render EPCR more susceptible to proteolytic cleavage, resulting in increased shedding of membrane-bound EPCR from the endothelial surface 30 and causing elevated protein C levels in the circulation 31 . We found evidence of a second, independent CAD association at rs6088590 (r 2 = 0, D′ = 0.01 with rs867186 in 1000 Genomes Project European samples; Supplementary   Fig. 8 ), an intronic SNP in NCOA6, with the T allele conferring increased risk of CAD (conditional on rs867186, conditional P = 1.14 × 10 −5 , OR = 0.97, 95% CI = 0.95-0.98). No additional SNPs were associated with CAD after conditioning on rs867186 and rs6088590 (P > 0.01).
Five of the new CAD-associated regions identified in the current analysis include genes that encode proteins expressed in smooth muscle cells (LMOD1, SERPINH1, DDX59-CAMSAP2, TNS1, PECAM1) 32, 33 . The CAD risk allele (T) of rs2820315, which is intronic in LMOD1, is associated with increased expression of LMOD1 in omental and subcutaneous adipose tissues 13, 34 (MuTHER, β = 0.11, P = 1.43 × 10 −11 ). The protein is found in smooth muscle cells (SMCs) 32, 33 . In vitro and transgenic mouse studies have demonstrated that CArG elements are essential for the expression of LMOD1 through both serum response factor (SRF) and myocardin (MYOCD) 35 . Myocardin has emerged as 
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COL4A1 -COL4A 2-COL4 A3 Figure 2 Plot showing the association of ~79,000 variants with CAD (−log 10 P) in up to 88,192 cases and 162,544 controls from the all-ancestry fixed-effects meta-analysis. The outer track represents the chromosomal number. SNPs are ordered by physical position. Blue dots represent known loci, and red dots are the new loci identified in the current study. Each association peak is labeled with the name of the closest gene(s) to the sentinel SNP. GWAS significance was set at −log 10 P ~7.3. No adjustments to P values to account for multiple testing have been made. l e t t e r s an important molecular switch for the programs of SMC and cardiac myocyte differentiation 36, 37 . The CAD-associated SNP (or tag) is an eQTL for IPO9 in peripheral blood mononuclear cells 38 ; however, given the previous biological evidence, LMOD1 would make the most plausible candidate gene in this region.
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rs1867624 is upstream of PECAM1, which encodes platelet/ endothelial cell adhesion molecule 1, a protein found on platelet, monocyte and neutrophil cell surfaces. The C allele is associated with reduced CAD risk ( Table 1) , increased expression of PECAM1 in peripheral blood mononuclear cells 38 (β = 0.1199, P = 1.38 × 10 −107 ) and is in LD with rs2070784 and rs6504218 (D′ = 1.0, r 2 > 0.8 in 1000 Genomes Project European samples), which are eQTLs for PECAM1 in aortic endothelial cells (P = 4.35 × 10 −13 ) and stimulated CD14 + monocytes (P < 1.7 × 10 −24 ), respectively (Supplementary Table 10 ) 39 . PECAM-1 has been implicated in the maintenance of integrity of the vascular barrier, the breach of which is a sign of inflammatory response. Failure to restore barrier function contributes to the development of chronic inflammatory diseases such as atherosclerosis. PECAM-1-expressing endothelial cell monolayers have been shown to exhibit increased steady-state barrier function, as well as more rapid restoration of barrier integrity following thrombin-induced perturbation, in comparison to PECAM-1-deficient cells 40 . Expression of PECAM-1 has been shown to be correlated with increased plaque burden in athero-susceptible regions of the aorta in mice 41 and also with decreased atherosclerotic area in the aorta overall 42 . Together, these findings prioritize PECAM1 as a candidate causal gene for this CAD-associated region in humans.
Of the 58 previously established CAD loci 3-9 , 47 were included on the CardioMetabochip. Forty-five regions were directionally concordant with the previous reports (2 were neutral), and 34 of these 45 (42 SNPs) had at least nominal evidence of association in a fixedeffects meta-analysis (P < 0.05) in either our European or all-ancestry studies with de novo genotyping (Supplementary Table 12 We have reported 15 new CAD associations, which, together with previous efforts, bring the total number of CAD-associated regions to 73. In addition to implicating atherosclerosis and traditional risk factors as mechanisms in the pathobiology of CAD, our discoveries highlight the potential importance of biological processes active in the arterial wall involving endothelial, smooth muscle and white blood cells and promote coronary atherogenesis. 
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Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper. CAD association results for the lead SNPs from the European and all-ancestry meta-analyses are reported. SNP allele frequencies for each ancestry group are provided in supplementary Figure 3 and supplementary table 5 for each of the studies with de novo genotyping. EA, effect allele; AF, effect allele frequency in Europeans; n, number of individuals in the analysis; OR, odds ratio; CI, confidence interval; log 10 (BF), log 10 of the Bayes factor obtained from MANTRA analyses (log 10 (BF) >6 is considered significant). There was no convincing evidence of heterogeneity at the new CAD-associated SNPs, P het ≥ 0.01. P values for heterogeneity across the data sets subjected to meta-analysis are provided in supplementary table 4, and I 2 statistics are provided in supplementary Figure 3 . Genome-wide significant results are shown in bold.
a Nonsynonymous SNP.
l e t t e r s Genotyping and quality control in studies with de novo genotyping. Samples from EPIC-CVD, CCHS, CIHDS, CGPS, BRAVE and PROMIS were genotyped on a customized version of the Illumina CardioMetabochip (referred to as 'Metabochip+' , Illumina), in two Illumina-certified laboratories located in Cambridge, UK, and Copenhagen, Denmark, by technicians masked to the phenotypic status of samples. The remaining studies were genotyped using the standard CardioMetabochip 10 in HudsonAlpha and Cedars Sinai (TAICHI 50 , WHI and ARIC 51 ) and the Broad Institute (MIGen).
Each collection was genotyped and underwent quality control separately ( Supplementary Tables 1 and 2) . In brief, studies genotyped on the Metabochip+ had genotypes assigned using Illumina GenCall software in GenomeStudio. Samples were removed if they had a call rate <0.97, if they had average heterozygosity >±3 s.d. from the overall mean heterozygosity or if their genotypic sex did not match their reported sex. One of each pair of duplicate samples and first-degree relatives (identified by a kinship coefficient >0.2) was removed.
Across all studies, SNP exclusions were based on MAF <0.01, P <1 × 10 −6 for Hardy-Weinberg equilibrium or call rate (CR) <0.97 (full details are given in Supplementary Table 2 ). These exclusions were also applied centrally to studies genotyped on the CardioMetabochip, namely the ARIC, WHI, MIGen and TAICHI studies. Principal-component analysis (PCA) was applied to identify and remove ancestral outliers. More stringent thresholds were adopted for SNPs used in the PCA for TAICHI and those studies genotyped on Metabochip+, namely CR <0.99, Hardy-Weinberg equilibrium P <1 × 10 −4 and MAF <0.05. In addition, one of each pair of SNPs in LD (r 2 > 0.2) was removed, as were variants in regions known to be associated with CAD.
SNP association analyses and meta-analyses. Statistical analyses were performed in R or PLINK 52 unless otherwise stated.
We collected sufficient samples to ensure the study was well powered to detect effect sizes in the range of OR = 1.05-1.10, which have typically been reported for CAD. With 88,000 cases, the study would have 88% power to detect OR = 1.05 for a SNP with MAF = 0.2 at α = 5 × 10 −8 , assuming a multiplicative model on the OR scale. For a lower MAF of 0.1, the study would have 93% power to detect OR = 1.07 at α = 5 × 10 −8 , assuming a multiplicative model. Power calculations were performed using Quanto.
Association with CAD was assessed in studies with de novo genotyping from European, South Asian and East Asian individuals, using the Genome-wide Efficient mixed-model analysis (GEMMA) approach 53 . This model includes both fixed effects and random effects of genetic inheritance. CAD (coded as 0/1) was the outcome variable; up to five principal components and the SNP of interest, coded additively, were included as fixed effects. P values from the score test are reported. The African-American studies were analyzed using a logistic model in PLINK, with CAD as the outcome variable and SNPs coded additively as the predictor. The covariates used by each study, including the number of principal components, are reported in the Supplementary Note.
Genomic inflation was at most 5% for any given study (Supplementary Fig.  1 and Supplementary Note). A subset of individuals from the PROMIS study and the EPIC-CVD consortium contributed to the CARDIoGRAMplusC4D 2013 report. To avoid any overlap of individuals in our studies with those in CARDioGRAMplusC4D, two analyses of these two studies were performed. One analysis included all the samples. A second analysis of the PROMIS and EPIC-CVD studies was performed after excluding all samples that had contributed to the CARDIoGRAMplusC4D study and before meta-analysis of our results with the results from the CARDIoGRAMplusC4D consortium. The CARDIoGRAMplusC4D SNP association results were converted onto the plus strand of GRh37, checked for heterogeneity and checked to ensure that allele frequencies were consistent with those for European populations.
Fixed-effects inverse-variance-weighted meta-analysis was used to combine results across studies in METAL 54 . Heterogeneity P values and I 2 values were calculated, and any SNP with P < 0.0001 for heterogeneity was removed. We performed two meta-analyses: the first involved just the European studies with de novo genotyping and the CARDIoGRAMplusC4D results to minimize ancestral diversity. The second involved all studies with de novo genotyping and the CARDIoGRAMplusC4D results to maximize sample size and statistical power. Given the ancestral diversity of the component studies with de novo genotyping, we also implemented meta-analyses with MANTRA 55 , a metaanalysis approach designed to handle trans-ancestry study designs. However, for our studies, the data were broadly consistent with the results from METAL ( Table 1 and Supplementary Table 4) , and we therefore primarily report the fixed-effect meta-analysis results.
Conditional association analyses.
Analyses to test for secondary association signals across seven regions with potential for independent signals were performed using GCTA 56 . GCTA implements a method for conducting conditional analyses using summary-level statistics (effect size, standard error, P value, effective sample size) and LD information (r 2 ) between SNPs estimated from a reference panel 56 . Conditional analyses were performed separately in CARDIoGRAMplusC4D, European, South Asian, and East Asian samples, and the results were combined using an inverse-variance-weighted fixed-effects meta-analysis approach. The conditional analyses were not performed in African-American samples because the SNP-level casecontrol counts were not made available for ARIC, MIGen and WHI. The 1000 Genomes Project Phase 3 v5 ancestry-specific reference panel was used to provide LD information (r 2 ) for the conditioned SNPs and other SNPs in the test regions for each of the three ancestry groups considered in the analyses. As approximately 9% of CARDIoGRAMplusC4D samples were South Asian and the remainder were European, to calculate LD for this data set, we sampled with replacement the genotypes of 50 individuals from the 1000 Genomes Project South Asian reference panel and combined them with the genotypes of the 503 European individuals available in the 1000 Genomes Project. To identify SNPs that were associated with CAD independently of the lead SNP in the test region, the association of each SNP in the region was tested conditioning on the most significant SNP in the overall meta-analysis of European, South Asian, East Asian and CARIoGRAMplusC4D samples. SNPs were identified as independent signals for a specific region if the conditional P value was ≤1 × 10 −4 . In each region, we performed several rounds of conditional analyses until the conditional P value was >1 × 10 −4 for all SNPs in the region. eQTL and epigenetic analyses. The MuTHER data set contains gene expression data from 850 UK twins for 23,596 probes and 2,029,988 (HapMap 2-imputed) SNPs. All cis-associated SNPs with FDR < 1% within each of the 15 newly identified CAD regions (IMPUTE info score > 0.8) were extracted from the MuTHER project data set for each of the tissues LCLs (n = 777), adipose (n = 776) and skin (n = 667).
The GTEx Project provides expression data from up to 449 individuals for 52,576 genes annotated in GENCODE v12 (including pseudogenes) and 6,820,472 genotyped SNPs (using the Human Omni5-Quad array).
In addition to the publicly available MuTHER and GTEx databases imputed to the HapMap and 1000 Genomes projects, respectively, we used a curated database of over 100 distinct eQTL data sets to determine whether our lead CAD-associated SNPs or SNPs in high LD with them (r 2 > 0.8 in Europeans from the HapMap or 1000 Genomes projects) were associated with the expres-
